AU751471B2

AU751471B2 - Method and kit for evaluation of HIV mutations

Info

Publication number: AU751471B2
Application number: AU92493/98A
Authority: AU
Inventors: James M. Dunn; Jean-Michel Lacroix
Original assignee: Visible Genetics Inc
Current assignee: Bayer Healthcare LLC
Priority date: 1997-09-26
Filing date: 1998-09-28
Publication date: 2002-08-15
Anticipated expiration: 2018-09-28
Also published as: WO1999016910A1; JP2001518313A; EP1017856A1; CA2302201A1; AU9249398A

Description

WO 99/16910 PCT/CA98/00913 -1- METHOD AND KIT FOR EVALUATION OF HIV MUTATIONS BACKGROUND OF THE INVENTION Genetic testing to determine the presence of or a susceptibility to a disease condition offers incredible opportunities for improved medical care, and the potential for such testing increases almost daily as ever increasing numbers of disease-associated genes and/or mutations are identified. A major hurdle which must be overcome to realize this potential, however, is the high cost of testing. This is particularly true in the case of highly polymorphic genes where the need to test for a large number of variations may make the test procedure appear to be so expensive that routine testing can never be achieved.

Testing for changes in DNA sequence can proceed via complete sequencing of a target nucleic acid molecule, although many persons in the art believe that such testing is too expensive to ever be routine. Changes in DNA sequence can also be detected by a technique called 'single-stranded conformational polymorphism" ("SSCP") described by Orita et al., Genomics 5: 874-879 (1989), or by a modification thereof referred to a dideoxy-fingerprinting described by Sarkar et al., Genomics 13: 4410443 (1992).

SSCP and ddF both evaluate the pattern of bands created when DNA fragments are electrophoretically separated on a non-denaturing electrophoresis gel. This pattern depends on a combination of the size of the fragments and of the three-dimensional conformation of the undenatured fragments. Thus, the pattern cannot be used for sequencing, because the theoretical spacing of the fragment bands is not equal.

The hierarchical assay methodology described in US Patent No. 5,545,527 and International Patent Publication No. WO 96/07761, which are incorporated herein by reference, provides a mechanism for systematically reducing the cost per test by utilizing a series of different test methodologies which may have significant numbers of results incorrectly indicating the absence of a genetic sequence of interest, but which rarely if ever yield a result incorrectly indicating the presence of such a genetic sequence. The tests employed in the hierarchy may frequently be combinations of different types of molecular tests, for examples combinations of immunoassays, oligonucleotide probe hybridization tests, oligonucleotide fragment analyses, and direct nucleic acid sequencing.

International Patent Publication No. WO 97/23650 discloses the evaluation of the allelic type of a polymorphic genetic locus by evaluation of less than all four of the bases of a nucleotide sequence. The invention of that application is exemplified with respect to determination of allelic type for HLA and typing of Chlamydial strains. There is no specific disclosure of probes for use in evaluation of HIV types.

This application relates to a particular series of tests which can be useful alone or as part of a hierarchical testing protocol for the detection and characterisation of human immunodeficiency virus (HIV).

SUMMARY OF THE INVENTION The invention provides in one form a method for determining the genetic type of HIV-i present in a sample containing HIV-1, comprising the steps of: 15 determining the positions of just the A and T nucleotides within the protease and reverse transcriptase genes and comparing these positions to the positions of the A and T nucleotides in known genetic types; if step does not provide an unambiguous identification performing a further sequencing reaction in which the position of all four bases are determined.

In an alternative form the invention provides a kit for performing A and T sequencing on an HIV-1 gene as in the method described above, the kit comprising: a plurality of A or T terminations mixtures, or both A and T termination mixtures, but no G termination mixture or C termination mixture, each of said A and T termination mixtures including one of a plurality of primer pairs, each pair flanking a different region of the HIV-1 genome, the pairs together flanking substantially all of the protease and reverse transcriptase genes, and at least one member of each pair being labelled with a detectable label.

11 January 2002 (16:34) 2a In a further alternative form the invention provides method for evaluating the sequence of a portion of an HIV genome in a sample, comprising the steps of: amplifying a portion of the HIV genome by a polymerase chain reaction using forward and reverse amplification primers to produce an amplicon, and determining sequence information for a portion of the amplicon by a sequencing procedure employing forward and reverse primers, characterised in that the sequence information includes the positions of at least one type of base, and the positions of different base types are determined in a hierarchical assay so as to minimise testing cost, and the forward amplification primers is selected from among the primers set *fe forth in Seq. ID Nos. 1, 3, 4 and o• :the reverse amplification primers is selected from among the primers set i 15 forth in Seq. ID Nos. 2, 6 and 7, and the sequencing primer is selected from among: as the forward sequencing primer, a primer as set forth in Seq. ID No.

j8, and as the reverse sequencing primer, a primer selected from among the primers oo 9 9o set forth in Seq. ID Nos. 9, 10 and 11; (ii) as the forward sequencing primer, a primer as set forth in Seq. ID No.

12, and as the reverse sequencing primer, a primer as set forth in Seq. ID No. 13; (iii) as the forward sequencing primer, a primer as set forth in Seq. ID No.

and as the reverse sequencing primer, a primer selected from among the primers set forth in Seq. ID Nos. 17, 18 and 19; and (iv) as the forward sequencing primer, a primer as set forth in Seq. ID No.

and as the reverse sequencing primer, a primer as set forth in Seq. ID No. 21.

The method of the invention provides a streamlined, hierarchical method for obtaining information about the allelic type of a sample of genetic material derived from an HIV-infected sample. It has been determined that 93 to 95% of the known variants of the protease and reverse transciptase genes of HIV can be Melbourne\003976448 Printed 11 January 2002 (16:34) determined by evaluating the positions of the A and T nucleotides within the sample. Thus, a substantial fraction of all mutational variations can be unequivocally identified by performing two initial sequencing reactions on the sample in which only ddA and ddT are used as chain terminators. For the small fraction of samples which are not identifiable based on the positions of these two bases, a second test is performed in which the sequence is determined in the 3'direction for all four bases. This test will identify substantially all of the remaining samples. For those for which an ambiguity remains, however, a final test in which the sequence of the sample is determined in both the 3' and 5-direction for all four bases is performed.

To perform the method of the invention, reagent suitable for performing the three tests within the hierarchy are suitably packaged as a kit containing two or more sub-kits. The first sub-kit contains reagents for performing A and T sequencing. The addition sub-kit(s) contains reagents for performing a four-base i 15 sequence determination on one or both strands of the target DNA. One-stranded sequence determination could be performed all in the 3'-direction, all in the direction, or as a combination of the two strands.

S Printed 11 January 2002 (16:34) WO 99/16910 PCT/CA98/00913 -3- BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 shows a schematic representation of the invention; and Figs. 2A and 2B shows the bases which are changed in known mutations of the protease and reverse transcriptase genes of HIV-1.

DETAILED DESCRIPTION OF THE INVENTION While the terminology used in this application is standard within the art, the following definitions of certain terms are provided to assure clarity.

1. "Allele" refers to a specific version of a nucleotide sequence at a polymorphic genetic locus.

2. "Polymorphic site" means a given nucleotide location in a genetic locus which is variable within a population.

3. "Gene" or "Genetic locus" means a specific nucleotide sequence within a given genome.

4. The "location" or "position" of a nucleotide in a genetic locus means the number assigned to the nucleotide in the gene, generally taken from the cDNA sequence or the genomic sequence of the gene.

The nucleotides Adenine, Cytosine, Guanine and Thymine are sometimes represented by their designations of A, C, G or T, respectively. Dideoxynucleotides which are used as chain terminators are abbreviated as ddA, ddC, ddG and ddT.

While it has long been apparent to persons skilled in the art that knowledge of the identity of the base at a particular location within a polymorphic genetic locus may be sufficient to determine the allelic type of that locus, this knowledge has not led to any modification of sequencing procedures. Rather, the knowledge has driven development of techniques such as allele-specific hybridization assays, and allele-specific ligation assays.

Despite the failure of the art to recognize the possibility, however, it is not always necessary to determine the sequence of all four nucleotides of a polymorphic genetic locus in order to determine which allele is present in a specific patient sample. As disclosed generally in International Patent Publication No. WO 97/23650, certain alleles of a genetic locus may be distinguishable on the basis of identification of the location of less than four, WO 99/16910 PCT/CA98/00913 -4and often only one nucleotide. This finding allows the development of the present method for improved allele identification within the highly polymorphic HIV genome.

Traditionally, if sequencing were going to be used to evaluate the allelic type of a polymorphic gene, four dideoxy nucleotide "sequencing" reactions of the type described by Sanger et al. (Proc. Natl. Acad. Sci. USA 74: 5463-5467 (1977)) would be run on the sample concurrently, and the products of the four reactions would then be analyzed by polyacrylamide gel electrophoresis. (see Chp 7.6, Current Protocols in Molecular Biology, Eds. Ausubel, F.M. et al, (John Wiley Sons; 1995)) In this wellknown technique, each of the four sequencing reactions generates a plurality of primer extension products, all of which end with a specific type of dideoxynucleotide. Each lane on the electrophoresis gel thus reflects the positions of one type of base in the extension product, but does not reveal the order and type of nucleotides intervening between the bases of this specific type. The information provided by the four lanes is therefore combined in known sequencing procedures to arrive at a composite picture of the sequence as a whole.

In the method of the invention the sequence of a good portion of the diagnostically relevant protease and reverse transcriptase genes is obtained in three steps: 1) cDNA is generated from the RNA present in the sample, and amplified, preferably across a region extending from 6 codons before the protease up to codon 335 of the reverse transcriptase of HIV-1 (the primer regions are not included in this range). 2) Sequencing reactions are performed at one or more of several hierarchical levels 3) Finally, the sequencing ladders are analyzed, preferably using the OpenGeneTM System: the Micro GeneBlasterTM DNA Sequencer, GeneObjectsTM and GeneLibrarianTM Softwares.

Fig. 1 shows one embodiment of the method of the invention schematically.

As shown, an RNA sample is obtained and treated by reverse transcriptase-PCR (RT- PCR) to produce an amplicon of approximately 1.3 kbase pairs spanning the protease and reverse transcriptase genes of the HIV genome from a target cell. This reaction can be performed using, for example, the TITANTM One-Tube RT-PCR system from Boehringer Mannheim (Cat. No. 1 855 476 or 1 882 382) using the following primers: CAGAARCAGG AGCHGAWAGA CA (forward) Seq ID No. 1 CTAYTARGTC TTTTGWTGGG TCATA (reverse) Seq ID No. 2 WO 99/16910 PCT/CA98/00913 Other primers which could be used at this step include: forward primers: AAGCAGGAGC CGATAGACAA GG Seq ID No. 3 AAGCAGGAGC TGAAAGACAG GG Seq ID No. 4 AAGCAGGAGC AGAAAGACAA GG Seq ID No. reverse primers: CAGAAGCAGG AGCCGAWAGA CA Seq ID No. 6 CTATTAAGTC TTTTGATGGG TCATA Seq ID No. 7 This amplicon is then combined with a master sequencing mixture containing buffer (260 mM Tris-HCL, pH 8.3; 32.5 mM MgCl2) and a polymerase enzyme such as Taq FS (Perkin Elmer/Applied Biosystems Cat No. 402070) This polymerase has a high rate of incorporartion of dideoxynucleotide relateive to the incorporation rate of, for example, conventional Taq polymerase. This mixture is used as stock in the subsequent reactions.

The first sequencing reaction performed in the method of the invention is a single-base sequencing reaction performed using either ddA or ddT in the sequencing mixture. This reaction is performed on the protease gene using the following primers: forward primer: GCCGATAGAC AAGGAACTG Seq ID N reverse primer ACTTTTGGGC CATCCATTCC T Seq ID N Alternate reverse primers which may be used are: ACTTTTGGGC CATCCATCCC T Seq ID No ACCTTTGGTC CATCCATTCC T Seq ID No o. 8 o.9 .11 For the reverse transcriptase gene, three sets of primers are used as follows: RT1 Primers forward: GTTAAACAAT GGCCATTGAC AGAAGA reverse: GGAATATTGC TGGTGATCCT TTCC Seq ID No. 12 Seq ID No. 13 PCT/CA98/00913 WO 99/16910 -6alternate forward: GTTAAACAAT GGCCATTGAC

AG

RT2 Primers forward: ATTAGATATC AGTACAATGT

GC

reverse: TCTGTATGTC ATTGACAGTC

CAGC

alternate reverse: TCTGTATATC ATTGACAGTC

CAGT

TCTGTATATC ATTGACAGTC

CAGC

TTCTGTATGT CATTGACAGT

CCAGC

RT3 Primers forward: GACTTAGAAA TAGGGCAGCA

TAGA

reverse: ATTAAGTCTT TTGATGGGTC

ATAA

Seq ID No. 14 Seq ID No. Seq ID No. 16 Seq ID No. 17 Seq ID No. 18 Seq ID No. 19 Seq ID No. Seq ID No. 21 When a sequencing device is employed which is capable of detecting and distinguishing two different fluorescent dyes (such as, for example, the ABI Prism Models 377, 310 or 373 or LiCor IR 2 System), both the forward and reverse primers are preferably each labeled with one of the two dyes. Forward and reverse sequencing fragments are then generated by thermally cycling the sample through multiple thermal cycles in the presence of either ddA or ddT. Analysis of the sequencing fragments produced using gel electrophoresis will allow the determination of the positions of both A and T bases. As shown in Figs. 2A and B, knowledge of the position of the A and T bases will identify of all known mutational variants within the reverse transcriptase gene and 93% of the variants within the protease gene. Thus, by performing a single reaction, the allelic type of majority of samples can be identified.

WO 99/16910 PCT/CA98/00913 -7- If the sequencer employed is only capable of evaluating a single base, then two reaction need to be employed. These may be a forward and backwards sequencing reaction both employing the same chain terminator (ddA or ddT), or two reaction performed in the same direction, one with ddA and one with ddT so that the positions of A and T bases are determined. These sequencing reactions can be employed using the same primers discussed above.

If the type of the HIV present in the sample cannot determined based upon the results of the first reaction, then a further sequencing reaction is performed on the sample stock to determine the positions of all four bases. Preferably, this is a sequencing reaction of intermediate complexity, involving the sequencing of one of the two strands of the DNA or a combination of the two strands making up one complete linear sequence. This can be done using the same primers identified above to obtain sequencing fragments.

Finally, if the intermediate test fails to provide unambiguous identification of the DNA type, sequencing of both strands may be performed. Again, the same sequencing primers identified above are used. Forward and reverse sequencing fragments can be produced in a single reaction using distinctively labeled forward and reverse primers, or in separate reactions depending on the nature of the detection system being employed.

Reagents suitable for practicing the method of the invention are suitably packaged in kit form. Thus, the invention provides a kit for analyzing the genetic type of an HIV-I gene in a sample using a hierarchical assay comprising, in separately packed combinations: a first subkit for performing A and T sequencing on HIV-1, comprising a plurality of A or T terminations mixtures, or both A and T termination mixtures, but no G termination mixture or C termination mixture, each of said A and T termination mixtures including one of a plurality of primer pairs, each pair flanking a different region of the HIV- I genome, the pairs together flanking substantially all of the protease and reverse transcriptase genes, and at least one member of each pair being labeled with a detectable label; and a second subkit for performing four base sequencingon HIV-1 comprising a plurality of A, C, G and T terminations mixtures, each of said termination mixtures including one of a plurality of primer pairs, each pair flanking a different region WO 99/16910 PCT/CA98/00913 -8of the HIV-1 genome, the pairs together flanking substantially all of the protease and reverse transcriptase genes, and at least one member of each pair being labeled with a detectable label. Additional subkits for performing four base sequencing may be included when intermediate and final assays on one strand and both strands are desired.

As used herein, the term "termination mixture" refers to a mixture containing a mixture of the four deoxunucleotide triphosphates (dATP, dCTP, dGTP, and dTTP), one species of chain terminating dideoxynucleotide (ddATP, ddCTP, ddGTP or ddTTP) and the appropriate sequencing primers.

The subkit for performing A and T sequencing on HIV-1 may also be provided separately for performing the initial determination of only the A and T nucleotides.

A

preferred kit of this type, whether provided separately or as part of a kit for performing a hierarchical assay has primer pairs in which each primer is labeled with a different an spectroscopically distinguishable fluorescent dye, such as Cy5.0 and Cy5.5 and includes only one of the two possible types of termination mixtures, for example just the T termination mixture.

The following examples are included to illustrate aspects of the instant invention and are not intended to limit the invention in any way.

Example 1 The variety or sub-type of HIV can be determined by Single Track Sequencing of a sample which has been amplifed by RT-PCR.

A reaction mixture is prepared as follows: 3 ul bound beads 3 ul sequencing primer (30 ng total) 2 ul 13X sequencing buffer (260 mM Tris-HCL, pH 9.5, 39 mM MgCl 2 2 ul Thermo Sequenase (Amersham Life Sciences, Cleveland) ((diluted 1:10 from stock to 3.2 U/ul) 3 ul distilled Final Volume: 13 ul The sequencing primer employed is the non-biotinylated primer of the sequencing template amplification reaction, but this time it is labeled with a detectable WO 99/16910 PCT/CA98/00913 -9label. The preferred label for detection on the MicroGene Blaster is Cy5.5 linked to the nucleotide of the primer.

CCATTCCTGG CTTTAATTTT ACTGG Seq ID No. 22 The reaction mixture is kept on ice. A single chain termination reaction mixture, in this case for the T nucleotide, is prepared by combining 750 uM of each of dATP, dCTP, dGTP and dTTP; and 2.5 uM of ddTTP. 3 ul of the termination reaction mix is place in a tube. 3 ul of the sequencing reaction mixture is added. An oil overlay is added and the single track reaction mixture is heated to 95 C for 2 mins in a PTC-100 Programmable Thermal Controller (MJ Research, Inc.) or Robocycler Gradient 96 (Stratagene) before being thermally processed for 25 cycles (or fewer if found to be satisfactory) as follows: Annealing: 50°C for 10 Sec.

Extension: 70 0 C for 30 Sec.

Denaturation: 95°C for 30 Sec.

After a final extension at 70 0 C for 5 min the sample is denatured at 95 0 C for sees and left on ice. The sample is mixed with 6 ul of STOP/Loading buffer containing 100% formamide and 5 mg/ml dye such as dextran blue.

1.5 ul of the mixture is loaded on a single lane of a MICROGENE

BLASTER

(Visible Genetics Inc., Toronto) and reaction products are separated by electrophoresis through a denaturing polyacrylamide gel. The reaction products are detected and presented with GENEOBJECTS software (Visible Genetics Inc., Toronto). The finger-print or barcode of the reaction products is compared to all known varieties of the pathogen nucleic acid sequence. An exact match is sought. If only one match is found, that subtype or variety is positively identified. If the patient sample had mixed varieties the result may show a heterogenous mix. The members of the heterogenous mix and relative quantities may be determined.

EXAMPLE2 WO 99/16910 PCT/CA98/00913 The variety or sub-type of the pathogen can be determined using CLIP

T

sequencing methodology. In this method the sequence of both the sense strand and antisense strand of the protease gene of HIV-1 may be obtained in a one step reaction as follows.

Combine the following materials and mix well: Concentration Volume Sequencing fragment DNA 3 ul PR211*Cy5.5 Primer 10 uM 0.5 ul PR526*Cy5.0 Primer 10 uM 0.5 ul diluted Thermosequenase Enzyme 3.2 U/ul 2 ul 13 X Reaction buffer 2 ul double distilled H20 5 ul TOTAL VOLUME 13.0 ul 13X reaction buffer consists of Tris-HCL 260 mM pH 8.3, MgCl 2 39 mM.

PR211 ATCACTCTTT GGCAACGACC Seq ID No. 23 PR526: CCATTCCTGG CTTTAATTTT ACTGG Seq ID No. 22 Place 3 ul of mixture into each of 4 tubes. Heat tubes to 94 0 C for 5 mins then reduce temperature to 85°C. Add and mix 3 ul of an 85°C dNTP/ddNTP solution containing 0.75 mM each dNTP and 2.5 uM of a chain terminating nucleotide triphosphate (ddNTP) (use a different ddNTP in each of the 4 tubes).

Treat the mixture to 60 cycles of the following thermal cycling reactions: 94°C for 10 sec, 62°C for 15 sec, 70°C for 1 min. Upon completion, treat the mixture for a final min at 70C and then store at 4°C until ready for loading. For viewing the reaction products, add an equal volume of stop/loading solution (95% formamide plus a colored dye). Take 1.5 ul and load in a single lane of a two dye MicroGene Blaster automated DNA sequencer (Visible Genetics Inc., Toronto).

WO 99/16910 PCT/CA98/00913 11 The reaction products from the both labeled primers are detected on the MICROGENE BLASTER as two separate traces, and displayed on GENEOBJECTS Software.

The base-called results from each primer were compared to the known protease gene sequences of HIV-1 and -2 by GENELIBRARIAN (a component of GENEOBJECTS (Visible Genetics Inc., Toronto). The sub-type of HIV-1 or HIV-2 is determined, and the presence of drug resistance codons is determined. Once the sequence of the HIV sub-type(s) is determined, it is reported to the patient file along with the quantitation data.

EXAMPLE 3 The RT-PCR is done on the HIV-1 RNA using the TitanTM One Tube RT-PCR System from Boehringer Mannheim. This RT-PCR is done on the RNA preparation obtained using the Amplicor T M HIV Monitor Test from Roche Diagnostic. It can also be done on the RNA extract for the NucliSense T M (formerly known as NASBA) HIV Viral Load from Organon Teknica.

All the reagents, tubes, tips, and other material needs to be RNase-free.

The recipe is made for 8 reactions (one strip of 8 tubes), including 10% extra. Thaw the RNA sample from the Amplicor HIV Monitor Test and keep on ice. This is the material obtained at step 14 of the section B "Specimen Preparation". If using RNA prepared for the NucliSense Assay, proceed the same way: thaw it and keep it on ice.

Take a 0.2 ml sterile, RNase-free, centrifuge tube, RNase-free, and prepare the RT-PCR Master Mix I (enough for 8 tubes, including 10% extra) by adding the following ingredient in the order listed: RT-PCR MASTER MIX I il of 100 mM DTT 13 pl of RNase-free dNTP 10 mM each dNTP 13 ul of forward PCR primer at 10 pM.

13 pl of reverse PCR primer at 10 gM Take a 0.2 ml sterile, RNase-free, centrifuge tube, RNase-free, and WO 99/16910 PCT/CA98/00913 12prepare the RT-PCR Master Mix II (enough for 8 tubes, including 20% extra) by adding the following ingredient in the order listed: RT-PCR MASTER MIX II pl of Titan 5X Buffer 5 gl of RNase Inhibitor 40 U/pl pl of Titan Enzyme.

18 pl of RNase-free MgC12 at 25 mM.

7 gl of RNase-free water Take one strip of 8 thin wall tubes. Add 8.5 pl of MASTER MIX I in each tube.

Add 11.5 gl of sample (RNA) to each tube. You may want to add a negative control per experiment. If using RNA extracted for the NucliSense Assay, dilute the sample 1:5 in RNase-free water and use 11.5 pl of this dilution.

Heat the RNA sample at 90 0 C for 3 min. using the program below:, cool at 50 0 C and add 10 pl of the MASTER MIX II in each tube (step 2 of the program below).

Be careful not to cross contaminate your samples.

Start the RT-PCR. Use the heated lid. When using the MJ-Plates, indicates that tubes are used when asked by the PTC-200. The following is the programming for the PTC-200: Calculated 1= 90.0° for 3:00 2= 50.00 for 5:00 3= 42.0°, 1:00:00 4= 94.0° for 3:00 5= 1.0°/s to 94.00 6= 94.00 for 0:20 7= 1.0 0 /s to 57.0° 8= 57.00 for 0:30 9= 1.0°/s to 68.00 10= 68.0° for 2:30 11=Goto5, 19 times WO 99/16910 PCT/CA98/00913 13- 12= 1.0°/s to 94.00 13= 94.0° for 0:20 14= 1.0 0 /s to 57.0° 57.0° for 0:30 16= 1.0 0 /s to 68.00 17= 68.00 for 3:00 18=Goto 12, 24 times 19= 68.00 for 7:00 4.0° for ever 21=End Store at -20 0 C or keep at 4 0 C and use immediately.

EXAMPLE 4 To determine the sequence of amplicon, 7 ul of each terminator mix (32 mixes when using a single dye instrument, 4 when using a two dye instrument) are combined with a 5 ul of a master mix as follows: MASTER MIX (single dye system)) 37 gl of buffer (260 mM Tris-HC1, pH 8.3, 32.5 mM MgC12) 145 gl of sterile water.

8 gl of undiluted TAQ FS 12 U/gl.

ul of the PCR product from Example 3 MASTER MIX (two-dye system) 18.5 ul of buffer 72.5 gl of sterile water 4 pl of undiluted TAQ FS 12 U/ul ul of the PCR product from Example 3 The two mixtures are mixed gently with a pipette tip. Add 8 gl of oil in each tube (optional), and start the thermocylcing reaction. The following is the programming for the PTC-200: Calculated WO 99/16910 PCT/CA98/00913 -14- 1= 94.0° for 5:00 2= 1.00/s to 94.00 3= 94.0° for 0:20 4= 1.0 0 /s to 56.00 5= 56.0° for 0:20 6= 1.0 0 /s to 70.00 7= 70.0° for 1:30 8=Goto 2, 47 times 9= 70.00 for 5:00 10= 4.0° for ever 1 =End The following master mixes are used in this example.

Termination mix for the protease one dye system.

A-Mix: 1.07 tM ddATP; 643 pIM dATP; 643 1 tM dCTP; 643 pM dGTP; 643 ptM dTTP; 330 nM each of forward and reverse primers C-Mix: 2.14 p.M ddCTP; 643 pM dATP; 643 p.M dCTP; 643 iM dGTP; 643 p.M dTTP; 330 nM each of forward and reverse primers G-Mix: 2.14 pM ddGTP; 643 pM dATP; 643 pM dCTP; 643 pM dGTP; 643 4.M dTTP; 330 nM each of forward and reverse primers T-Mix: 2.14 4M ddTTP; 643 pM dATP; 643 ptM dCTP; 643 p.M dGTP; 643 ptM dTTP; 330 nM each of forward and reverse primers One primer in each pair is labeled.

Termination mix for the first region of reverse transcriptase (one dye system) A-Mix: 1.07 pM ddATP; 643 pM dATP; 643 p M dCTP; 643 p.M dGTP; 643 pM dTTP; 330 nM each of forward and reverse primers C-Mix: 2.14 pM ddCTP; 643 irM dATP; 643 gpM dCTP; 643 pM dGTP; 643 pM dTTP; 330 nM each of forward and reverse primers G-Mix: 2.14 pM ddGTP; 643 4M dATP; 643 4.M dCTP; 643 pM dGTP; 643 pM dTTP; 330 nM each of forward and reverse primers WO 99/16910 PCT/CA98/00913 T-Mix: 2.14 p.M ddTTP; 643 [tM dATP; 643 pM dCTP; 643 pM dGTP; 643 pM dTTP; 330 nM each of forward and reverse primers One primer of eachpair is labeled.

Termination mix for the second region of reverse transcriptase (one dye system) A-Mix: 1.07 gM ddATP; 643 pM dATP; 643 gpM dCTP; 643 p.M dGTP; 643 4tM dTTP; 330 nM each of forward and reverse primers C-Mix: 2.14 p.M ddCTP; 643 pM dATP; 643 pM dCTP; 643 pM dGTP; 643 pM dTTP; 330 nM each of forward and reverse primers G-Mix: 2.14 pM ddGTP; 643 pM dATP; 643 pM dCTP; 643 p.M dGTP; 643 pM dTTP; 330 nM each of forward and reverse primers T-Mix: 2.14 pM ddTTP; 643 pM dATP; 643 pM dCTP; 643 pM dGTP; 643 pM dTTP; 330 nM each of forward and reverse primers One primer is each pair is labeled.

Termination mix for the third region of the reverse transcriptase (single dye system) A-Mix: 1.07 gpM ddATP; 643 4M dATP; 643 p.M dCTP; 643 pM dGTP; 643 pM dTTP; 330 nM each of forward and reverse primers C-Mix: 2.14 pM ddCTP; 643 pM dATP; 643 p.M dCTP; 643 pM dGTP; 643 pM dTTP; 330 nM each of forward and reverse primers G-Mix: 2.14 pM ddGTP; 643 pM dATP; 643 |pM dCTP; 643 pM dGTP; 643 pM dTTP; 330 nM each of forward and reverse primers T-Mix: 2.14 pM ddTTP; 643 piM dATP; 643 pM dCTP; 643 pM dGTP; 643 [LM dTTP; 330 nM each of forward and reverse primers One dye in each reaction is labeled.

Termination mixes for two dye systems Protease A-Mix: 1.07 pM ddATP; 643 pM dATP; 643 pM dCTP; 643 pM dGTP; 643 pM dTTP; 330 nM each of forward and reverse primers C-Mix: 2.14 pM ddCTP; 643 pM dATP; 643 piM dCTP; 643 ptM dGTP; 643 pM dTTP; WO 99/16910 PCT/CA98/00913 -16- 330 nM each of forward and reverse primers G-Mix: 2.14 pM ddGTP; 643 pM dATP; 643 piM dCTP; 643 pM dGTP; 643 pM dTTP; 330 nM each of forward and reverse primers T-Mix: 2.14 pM ddTTP; 643 pM dATP; 643 pM dCTP; 643 pM dGTP; 643 jiM dTTP; 330 nM each of forward and reverse primers Both primers are labeled, for example with Cy5.0 and Cy5.5, respectively.

First RT region A-Mix: 1.07 pM ddATP; 643 pM dATP; 643 p.M dCTP; 643 pM dGTP; 643 pM dTTP; 330 nM each of forward and reverse primers C-Mix: 2.14 tM ddCTP; 643 pM dATP; 643 pM dCTP; 643 tM dGTP; 643 pM dTTP; 330 nM each of forward and reverse primers G-Mix: 2.14 pM ddGTP; 643 4M dATP; 643 pM dCTP; 643 pM dGTP; 643 pM dTTP; 330 nM each of forward and reverse primers T-Mix: 2.14 pM ddTTP; 643 piM dATP; 643 pM dCTP; 643 pM dGTP; 643 pM dTTP; 330 nM each of forward and reverse primers Both primers are labeled, for example with Cy5.0 and Cy5.5, respectively.

Second reverse transcriptase region A-Mix: 1.07 pM ddATP; 643 pM dATP; 643 pM dCTP; 643 pM dGTP; 643 jiM dTTP; 330 nM each of forward and reverse primers C-Mix: 2.14 pM ddCTP; 643 pM dATP; 643 pM dCTP; 643 pM dGTP; 643 pM dTTP; 330 nM each of forward and reverse primers G-Mix: 2.14 pM ddGTP; 643 ptM dATP; 643 pM dCTP; 643 pM dGTP; 643 pM dTTP; 330 nM each of forward and reverse primers T-Mix: 2.14 pM ddTTP; 643 pM dATP; 643 pM dCTP; 643 pM dGTP; 643 pM dTTP; 330 nM each of forward and reverse primers Both primers are labeled, for example with Cy5.0 and Cy5.5, respectively.

Third reverse transcriptase region A-Mix: 1.07 pM ddATP; 643 pM dATP; 643 pM dCTP; 643 pM dGTP; 643 pM dTTP; WO 99/16910 PCT/CA98/00913 17- 330 nM each of forward and reverse primers C-Mix: 2.14 piM ddCTP; 643 R.M dATP; 643 g~M dCTP; 643 piM dGTP; 643 piM dTTP; 330 nM each of forward and reverse primers G-Mix: 2.14 RM ddGTP; 643 gM dATP; 643 pM dCTP; 643 pM dGTP; 643 pM dTTP; 330 nM each of forward and reverse primers T-Mix: 2.14 RM ddTTP; 643 RM dATP; 643 RM dCTP; 643 gM dGTP; 643 gM dTTP; 330 nM each of forward and reverse primers Both primers are labeled, for example with Cy5.0 and Cy5.5, respectively.

EDITORIAL NOTE NO: 92493/98 SEQUENCE LISTING PAGES 1/8 TO 8/8 FOLLOW PAGE 17 OF THE DESCRIPTION.

WO 99/16910 1 8 PCT/CA98/00913 SEQUENCE LISTING GENERAL INFORMATION: APPLICANT: Visible Genetics Inc.

Dunn, James M.

Lacroix, Jean-Michel (ii) TITLE OF INVENTION: Method and Kit for Evaluation of HIV Mutations (iii) NUMBER OF SEQUENCES: 23 (iv) CORRESPONDENCE ADDRESS:

ADDRESSEE:

STREET:

CITY:

STATE:

COUNTRY:

ZIP:

COMPUTER READABLE FORM: MEDIUM TYPE: Diskette 3.5 inch, 1.44 Mb storage COMPUTER: IBM compatible OPERATING SYSTEM: MS DOS SOFTWARE: Word Perfect (vi) CURRENT APPLICATION DATA APPLICATION NUMBER: FILING DATE:

CLASSIFICATION:

(vii) PRIOR APPLICATION DATA: APPLICATION NUMBER: FILING DATE: (viii) ATTORNEY/AGENT INFORMATION

NAME:

REGISTRATION NUMBER: REFERENCE/DOCKET NUMBER: (ix) TELECOMMUNICATION INFORMATION:

TELEPHONE:

TELEFAX:

TELEX:

INFORMATION FOR SEQ ID NO: 1: SEQUENCE CHARACTERISTICS: LENGTH: 22 TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: yes FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: ORGANISM: HIV (ix) FEATURE: OTHER INFORMATION: amplification primer for HIV (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: CAGAARCAGG AGCHGAWAGA CA 22 INFORMATION FOR SEQ ID NO: 2: SEQUENCE CHARACTERISTICS: SUBSTITUTE

SHEET

2 2 WO 99/16910 PCT/CA98/00913 LENGTH: TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: ORGANISM: HIV (ix) FEATURE: OTHER INFORMATION: amplification primer for HIV (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: CTAYTARGTC TTTTGWTGGG TCATA INFORMATION FOR SEQ ID NO: 3: SEQUENCE CHARACTERISTICS: LENGTH: 22 TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: yes FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: ORGANISM: HIV (ix) FEATURE: OTHER INFORMATION: amplification primer for HIV (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: AAGCAGGAGC CGATAGACAA GG 22 INFORMATION FOR SEQ ID NO: 4: SEQUENCE CHARACTERISTICS: LENGTH: 22 TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: yes FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: ORGANISM: HIV (ix) FEATURE: OTHER INFORMATION: amplification primer for HIV (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: AAGCAGGAGC TGAAAGACAG GG 22 INFORMATION FOR SEQ ID NO: SEQUENCE CHARACTERISTICS: LENGTH: 22 TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear SUBSTITUTE SHEET (RULE 26) 3/8 WO 99/16910 PCT/CA98/00913 (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: yes FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: ORGANISM: HIV (ix) FEATURE: OTHER INFORMATION: amplification primer for HIV (xi) SEQUENCE DESCRIPTION: SEQ ID NO: AAGCAGGAGC AGAAAGACAA GG 22 INFORMATION FOR SEQ ID NO: 6: SEQUENCE CHARACTERISTICS: LENGTH: 22 TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: ORGANISM: HIV (ix) FEATURE: OTHER INFORMATION: amplification primer for HIV (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: CAGAAGCAGG AGCCGAWAGA CA 22 INFORMATION FOR SEQ ID NO: 7: SEQUENCE CHARACTERISTICS: LENGTH: TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: ORGANISM: HIV (ix) FEATURE: OTHER INFORMATION: amplification primer for HIV (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: CTATTAAGTC TTTTGATGGG TCATA INFORMATION FOR SEQ ID NO: 8: SEQUENCE CHARACTERISTICS: LENGTH: 19 TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE:- other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: yes FRAGMENT TYPE: internal SUBSTITUTE SHEET (RULE 26) WO 99/16910 4 8 PCT/CA98/00913 (vi) ORIGINAL SOURCE: ORGANISM: HIV (ix) FEATURE: OTHER INFORMATION: sequencing primer for HIV (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: GCCGATAGAC AAGGAACTG 19 INFORMATION FOR SEQ ID NO: 9: SEQUENCE CHARACTERISTICS: LENGTH: 21 TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: ORGANISM: HIV (ix) FEATURE: OTHER INFORMATION: sequencing primer for HIV (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: ACTTTTGGGC CATCCATTCC T 21 INFORMATION FOR SEQ ID NO: SEQUENCE CHARACTERISTICS: LENGTH: 21 TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: ORGANISM: HIV (ix) FEATURE: OTHER INFORMATION: sequencing primer for HIV (xi) SEQUENCE DESCRIPTION: SEQ ID NO: ACTTTTGGGC CATCCATCCC T 21 INFORMATION FOR SEQ ID NO: 11: SEQUENCE CHARACTERISTICS: LENGTH: 21 TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: ORGANISM: HIV (ix) FEATURE: OTHER INFORMATION: sequencing primer for HIV SUBSTITUTE SHEET (RULE 26) WO 99/16910 5 8 PCT/CA98/00913 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: ACCTTTGGTC CATCCATTCC T 21 INFORMATION FOR SEQ ID NO: 12: SEQUENCE CHARACTERISTICS: LENGTH: 26 TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: yes FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: ORGANISM: HIV (ix) FEATURE: OTHER INFORMATION: sequencing primer for HIV (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: GTTAAACAAT GGCCATTGAC AGAAGA 26 INFORMATION FOR SEQ ID NO: 13: SEQUENCE CHARACTERISTICS: LENGTH: 24 TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: ORGANISM: HIV (ix) FEATURE: OTHER INFORMATION: sequencing primer for HIV (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: GGAATATTGC TGGTGATCCT TTCC 24 INFORMATION FOR SEQ ID NO: 14: SEQUENCE CHARACTERISTICS: LENGTH: 22 TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: yes FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: ORGANISM: HIV (ix) FEATURE: OTHER INFORMATION: sequencing primer for HIV (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: GTTAAACAAT GGCCATTGAC AG 22 SUBSTITUTE SHEET (RULE 26) 6/8 AA m A A WO 99/16910 PCT/CA98/00913 INFORMATION FOR SEQ ID NO: SEQUENCE CHARACTERISTICS: LENGTH: 22 TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no 1 (iv) ANTI-SENSE: yes FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: ORGANISM: HIV (ix) FEATURE: OTHER INFORMATION: sequencing primer for HIV (xi) SEQUENCE DESCRIPTION: SEQ ID NO: ATTAGATATC AGTACAATGT GC 22 INFORMATION FOR SEQ ID NO: 16: SEQUENCE CHARACTERISTICS: LENGTH: 24 TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: ORGANISM: HIV (ix) FEATURE: OTHER INFORMATION: sequencing primer for HIV (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16: TCTGTATGTC ATTGACAGTC CAGC 24 INFORMATION FOR SEQ ID NO: 17: SEQUENCE CHARACTERISTICS: LENGTH: 24 TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: ORGANISM: HIV (ix) FEATURE: OTHER INFORMATION: sequencing primer for HIV (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17: TCTGTATATC ATTGACAGTC CAGT 24 INFORMATION FOR SEQ ID NO: 18: SEQUENCE CHARACTERISTICS: LENGTH: 24 TYPE: nucleic acid SUBSTITUTE SHEET (RULE 26) WO 99/16910 8 PCT/CA98/00913 STRANDEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: ORGANISM: HIV (ix) FEATURE: OTHER INFORMATION: sequencing primer for HIV (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18: TCTGTATATC ATTGACAGTC CAGC 24 INFORMATION FOR SEQ ID NO: 19: SEQUENCE CHARACTERISTICS: LENGTH: TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: ORGANISM: HIV (ix) FEATURE: OTHER INFORMATION: sequencing primer for HIV (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: TTCTGTATGT CATTGACAGT CCAGC INFORMATION FOR SEQ ID NO: SEQUENCE CHARACTERISTICS: LENGTH: 24 TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: yes FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: ORGANISM: HIV (ix) FEATURE: OTHER INFORMATION: sequencing primer for HIV (xi) SEQUENCE DESCRIPTION: SEQ ID NO: GACTTAGAAA TAGGGCAGCA TAGA 24 INFORMATION FOR SEQ ID NO: 21: SEQUENCE CHARACTERISTICS: LENGTH: 24 TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid SUBSTITUTE SHEET (RULE 26) WO 99/16910 PCT/CA98/00913 (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: ORGANISM: HIV (ix) FEATURE: OTHER INFORMATION: sequencing primer for HIV (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21: ATTAAGTCTT TTGATGGGTC ATAA 24 INFORMATION FOR SEQ ID NO: 22: SEQUENCE CHARACTERISTICS: LENGTH: TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: ORGANISM: HIV (ix) FEATURE: OTHER INFORMATION: sequencing primer for HIV (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22: CCATTCCTGG CTTTAATTTT ACTGG INFORMATION FOR SEQ ID NO: 23: SEQUENCE CHARACTERISTICS: LENGTH: TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: yes FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: ORGANISM: HIV (ix) FEATURE: OTHER INFORMATION: sequencing primer for HIV (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23: ATCACTCTTT GGCAACGACC SUBSTITUTE SHEET (RULE 26)

Claims

1. A method for determining the genetic type of HIV-1 present in a sample containing HIV- 1, comprising the steps of: determining the positions of just the A and T nucleotides within the protease and reverse transcriptase genes and comparing these positions to the positions of the A and T nucleotides in known genetic types; if step does not provide an unambiguous identification performing a further sequencing reaction in which the position of all four bases are determined.

2. The method of claim 1, wherein the positions of just the A and T nucleotides are determined by performing a cycled reaction that generates both forward and 15 reverse sequencing fragments using two primers, each primer labelled with a different and distinguishable detectable label. o#

3. The method of claim 2, wherein the label is fluorescent label. 20 4. A kit when used for performing A and T sequencing on an HIV-1 gene in the "method of any one of claims 1 to 3, the kit comprising: a plurality of A or T terminations mixtures, or both A and T termination mixtures, but no G termination mixture or C termination mixture, each of said A and T termination mixtures including one of a plurality of primer pairs, each pair **oo 25 flanking a different region of the HIV-1 genome, the pairs together flanking substantially all of the protease and reverse transcriptase genes, and at least one member of each pair being labelled with a detectable label. 004080514 18ox A kit when used for analysing the genetic type of an HIV-I gene in a sample using a hierarchical assay in the method of any one of claims 1 to 3, the kit comprising, in separately packed combinations: a first subkit for performing A and T sequencing on HIV-I, comprising a plurality of A or T terminations mixtures, or both A and T termination mixtures, but no G termination mixture or C termination mixture, each of said A and T termination 0* 0000 0* 0 0 00* 0•g0 go go 0 0 0 o*o 0 0o00 o* o 0000 0 19 WO 99/16910 PCT/CA98/00913 6 7 -8 9 11 12 13 14 1 2 3 4 6 7 8 1 2 3 4 6 .7 8 mixtures including one of a plurality of primer pairs. each pair flanking a different region of the HIV-1 genome, the pairs together flanking substantially all of the protease and reverse transcriptase genes, and at least one member of each pair being labeled with a detectable label; and a second subkit for performing four base sequencing on HIV-1 comprising a plurality of A, C, G and T terminations mixtures, each of said termination mixtures including one of a plurality of primer pairs, each pair flanking a different region of the HIV-1 genome, the pairs together flanking substantially all of the protease and reverse transcriptase genes, and at least one member of each pair being labeled with a detectable label.

6. The kit according to claim 4 or 5, wherein the primers include a primer pair for sequencing of the protease gene comprising a forward primer of the sequence GCCGATAGAC AAGGAACTG Seq ID No. 8 and a reverse primer selected from among ACTTTTGGGC CATCCATTCC T Seq ID No. 9 ACTTTTGGGC CATCCATCCC T Seq ID No. and ACCTTTGGTC CATCCATTCC T. Seq ID No. 11

7. The kit according to any of claims 4 to 6 wherein the primers include a primer pair for sequencing of a portion of the reverse transcriptase gene comprising a forward primer selected from among GTTAAACAAT GGCCATTGAC AGAAGA Seq ID No. 1; and GTTAAACAAT GGCCATTGAC AG Seq ID No. 14 and a reverse primer having the sequence GGAATATTGC TGGTGATCCT TTCC. Sea ID No. 13 2 4 SUBSTITUTE SHEET (RULE 26) WO 99/16910 20 PCT/CA98/00913 1 8. The kit according to any of claims 4 to 7, wherein the primers include a 2 primer pair for sequencing of a portion of the reverse transcriptase gene comprising a 3 forward primer having the sequence 4 ATTAGATATC AGTACAATGT GC Seq ID No. and a reverse primer selected from among 6 TCTGTATGTC ATTGACAGTC CAGC Seq ID No. 16 7 TCTGTATATC ATTGACAGTC CAGT Seq ID No. 17 8 TCTGTATATC ATTGACAGTC CAGC Seq ID No. 18 9 and, TTCTGTATGT CATTGACAGT CCAGC. Seq ID No. 19 1 9. The kit according to any of claims 4 to 8, wherein the primers include a 2 primer pair for sequencing of a portion of the reverse transcriptase gene comprising a 3 forward primer having the sequence 4 GACTTAGAAA TAGGGCAGCA TAGA Seq ID No. and a reverse primer having the sequence 6 ATTAAGTCTT TTGATGGGTC ATAA. Seq ID No. 21 1 10. The kit according to any of claims 4-9, wherein the primers in each 2 primer pair are labeled with different and spectroscopically distinguishable fluorescent 3 labels. 1 SUBSTITUTE SHEET (RULE 26)

11. A kit for determination of sequence information from a polynucleotide derived from the protease gene an HIV sample, comprising: as a forward sequencing primer, a primer as set forth in Seq. ID No. 8, and a reverse sequencing primer selected from among the primers set forth in Seq. ID. Nos. 9, 10 and 11.

12. A kit for determination of sequence information from a polynucleotide derived from the reverse transcriptase gene an HIV sample, comprising: the sequencing primers as set forth in Seq. ID Nos. 12, 13, 15, 20 and 21 and one sequencing primer selected from among the primers set forth in Seq. ID Nos. 17, 18 and 19. a forward amplification primer selected from among the primers set forth in Seq. ID Nos. 1, 3, 4 and 5; and 0**00 a reverse amplification primer selected from among the primers set forth in oooe Seq. ID. Nos. 2, 6 and 7. 20 14. A method for evaluating the sequence of a portion of an HIV genome in a sample, comprising the steps of: amplifying a portion of the HIV genome by a polymerase chain reaction using forward and reverse amplification primers to produce an amplicon, and determining sequence information for a portion of the amplicon by a sequencing procedure employing forward and reverse primers, characterised in that the sequence information includes the positions of at least one type of base, and the positions of different base types are determined in a hierarchical assay so as to minimise testing cost, and (16:34) 22 the forward amplification primers is selected from among the primers set forth in Seq. ID Nos. 1, 3, 4 and the reverse amplification primers is selected from among the primers set forth in Seq. ID Nos. 2, 6 and 7, and the sequencing primer is selected from among: as the forward sequencing primer, a primer as set forth in Seq. ID No. 8, and as the reverse sequencing primer, a primer selected from among the primers set forth in Seq. ID Nos. 9, 10 and 11; (ii) as the forward sequencing primer, a primer as set forth in Seq. ID No. 12, and as the reverse sequencing primer, a primer as set forth in Seq. ID No. 13; (iii) as the forward sequencing primer, a primer as set forth in Seq. ID No. and as the reverse sequencing primer, a primer selected from among the primers set forth in Seq. ID Nos. 17, 18 and 19; and as the forward sequencing primer, a primer as set forth in Seq. ID No. 20, and as the reverse sequencing primer, a primer as set forth in Seq. ID No. 21. DATED: 11 January 2002 FREEHILLS CARTER SMITH BEADLE 20 Patent Attorneys for the Applicant: VISIBLE GENETICS INC Printed 1 1-January 2002 (16:34)